SCHEMBL2349223

SCHEMBL2349223

OCc1cc(Oc2ccccc2)cc(Oc2ccccc2)c1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.69
TTR P02766 1/20 0.56
TSHR P16473 3/20 0.52
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
NLRP3 Q96P20 1/20 0.47
NR1H2 P55055 1/20 0.46
BAX Q07812 1/20 0.46
RHEB Q15382 3/20 0.45
FFAR1 O14842 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GSTP1 P09211 1/20 0.44
ST14 Q9Y5Y6 1/20 0.43
SRD5A2 P31213 1/20 0.43
AKR1C3 P42330 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2351067 0.88 LTA4H (0.60) LTA4HTTRTSHRNR1H2BAX
SCHEMBL11396620 0.87 LTA4H (0.58) LTA4HTTRTSHRRHEB
SCHEMBL11113359 0.86 LTA4H (0.53) LTA4HTTRTSHRMEN1NPC1
SCHEMBL9999625 0.86 CYP4F2 (0.55) LTA4HTTRTSHRMEN1RAB9A
SCHEMBL29661187 0.85 LTA4H (0.67) LTA4HTTRTSHRFFAR1HSD17B10
SCHEMBL358425 0.85 LTA4H (0.67) LTA4HTTRTSHRFFAR1HSD17B10
SCHEMBL2346727 0.85 LTA4H (0.51) LTA4HTTRTSHRRHEBFFAR1
Diphenylether SCHEMBL27843672 0.84 LTA4H (0.86) LTA4HTTRTSHRMEN1KMT2A
SCHEMBL15831788 0.83 LTA4H (0.84) LTA4HTTRTSHRMEN1KMT2A
Methane SCHEMBL10579323 0.83 LTA4H (0.64) LTA4HTTRTSHRFFAR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 LTA4H 1418/4885TTR 4393/4885TSHR 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.